Skip to main content
. Author manuscript; available in PMC: 2010 Jan 15.
Published in final edited form as: Cancer Res. 2009 Jan 15;69(2):700–708. doi: 10.1158/0008-5472.CAN-08-3157

Figure 1. Prostate cancer cell lines profiled for ASS expression and ADI-PEG20 sensitivity.

Figure 1

A, RWPE-1, LNCaP, PC3, and CWR22Rv1 were examined for ASS mRNA by RT-PCR and B, ASS protein by immunoblotting. C, Immunoblot for 10nM DHT timecourse of LNCaP against α-ASS. D, Cell lines were treated by ADI-PEG20 at 0.02, 0.04, 0.08, 0.15, 0.3, 0.6, 1.2, and 2.4μg/mL for 3 (PC3) or 6 days before MTT assay. Values are reported as mean±SD.